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ABSTRACT
Corynebacterium urealyticum, formerly known as coryneform CDC group D2, was first recognized to be
involved in human infections 30 years ago. It is a slow-growing, lipophilic, asaccharolytic and usually
multidrug-resistant organism with potent urease activity. Its cell wall peptidoglycan, menaquinone,
mycolic and cellular fatty acid composition is consistent with that of the genus Corynebacterium. DNA–
DNA hybridization studies and 16S rDNA sequencing analysis have been used to determine the degree of
relatedness of C. urealyticum to other corynebacterial species. The genome of the type strain consists of a
circular chromosome with a size of 2 369 219 bp and a mean G + C content of 64.2%, and analysis of its
genome explains the bacterium’s lifestyle. C. urealyticum is a common skin colonizer of hospitalized
elderly individuals who are receiving broad-spectrum antibiotics. It is an opportunistic pathogen causing
mainly acute cystitis, pyelonephritis, encrusted cystitis, and encrusted pyelitis. More infrequently, it
causes other infections, but mainly in patients with urological diseases. Infections are more common in
males than in females, and treatment requires administration of antibiotics active against the organism
in vitro, mainly glycopeptides, as well as surgical intervention, the latter mostly in cases of chronic
infection. Mortality directly associated with infection by this organism is not frequent, but encrusted
pyelitis in kidney-recipient patients may cause graft loss. The outcome of infection by this organism is
reasonably good if the microbiological diagnosis is made and patients are treated appropriately.
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HISTORY
Isolation of urease-positive coryneforms from
urine samples in cases of encrusted cystitis was
reported in 1945 [1] and later [2], but such
corynebacteria were not well characterized.
A non-spore-forming, aerobic and Gram-posi-
tive bacillus with strong urease activity was
described by King in 1972 as coryneform CDC
group D2 [3]. In 1979, Jacobs and Perlino
described a case of pneumonia in a debilitated
patient from whom such an organism was iso-
lated [4]. This organism was implicated for the
first time in urinary tract infections (UTIs) in a
report published in 1985 [5] concerning four
patients with alkaline encrusted cystitis. In the
same year, eight cases of UTI caused by this
organism were also reported [6], and 2 years later,
a report concerning 43 patients with asymptom-
atic bacteriuria, cystitis, acute pyelonephritis with
bacteraemia, encrusted cystitis and wound infec-
tion was published [7]. These results were
expanded and confirmed 3 years later in the
largest series reported so far [8].
After different taxonomic studies, it was con-
cluded that coryneform CDC group D2 was a true
Corynebacterium species, different from all others
known, and it was named Corynebacterium urea-
lyticum, stressing its strong ability to split urea [9].
Recently, the complete genome sequence of
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C. urealyticum has been determined [10]. Interpre-
tation of genome sequences requires a ‘Rosetta
Stone’ to decode biological information in the
finest detail, just as the deciphering of the ancient
Egyptian hieroglyphics required the original
Rosetta Stone. The combination of genomics and
bioinformatics constitutes a discipline that has
now been applied to understanding the genome
of a stone-forming bacterial pathogen.
TAXONOMIC FEATURES
The taxonomic classification of C. urealyticum
(CDC coryneform group D2) was originally based
on biochemical characteristics [9,11,12]. The cell
wall peptidoglycan of C. urealyticum contains
meso-diaminopimelic acid, and arabinose and
galactose are the major cell wall sugars. The
major menaquinone is MK-9(H2). Tuberculostea-
ric acid and short-chain mycolic acids (C26–C36)
are present [11,13]. Members of the species
C. urealyticum are characterized by their potent
ability to hydrolyze urea [5,14] and by their
failure to produce acid from carbohydrates
[9,14]. Moreover, DNA–DNA hybridization stud-
ies [9,12] and 16S rRNA sequence analysis [15,16]
were used to determine the degree of relatedness
of C. urealyticum to other corynebacterial species.
On the basis of small-subunit rRNA sequence
data, a close phylogenetic relationship between
C. urealyticum and C. jeikeium was observed
[15,16]. More recently, this analysis was comple-
mented by using partial sequences of the RNA
polymerase beta-subunit gene (rpoB) in phyloge-
netic studies of corynebacteria [17,18]. Both
C. urealyticum and C. jeikeium are strict aerobes
that exhibit lipid-requiring and multidrug-resis-
tance phenotypes [19] and belong to a separate
branch in the genus Corynebacterium [16,17].
However, C. jeikeium can be differentiated from
C. urealyticum because it is non-urealytic and
produces acid from glucose [19,20].
A recent study demonstrated that cellular fatty
acid analysis is a powerful method for the reliable
identification and differentiation of corynebacte-
rial species [21]. The cellular fatty acid composi-
tion of C. urealyticum is consistent with that of the
genus Corynebacterium, with the majority of cellu-
lar fatty acids being of the straight-chain, mono-
unsaturated types [11,21]. In addition, small
amounts of tuberculostearic acid were consis-
tently detected in several studies [11,13,21].
A comparative study on the phospholipid com-
position of C. urealyticum, C. jeikeium and C. amy-
colatum strains revealed significant differences
related to the acyl chains of the glycerol moiety
of these compounds, and most notably, the
presence of high levels of a 10-methyleneocta-
decanoyl moiety in the detected inositol-contain-
ing phospholipids of C. urealyticum [22].
DNA–DNA hybridization studies for intraspe-
cies comparison revealed tight hybridization
groups of C. urealyticum strains that were distinct
from validly established species [9,12]. The high
levels of interstrain DNA homology were consis-
tent with the criterion of a homogenous species.
Ribotyping (rRNA gene restriction length poly-
morphism) of C. urealyticum strains from urine
samples and skin infections was used for epide-
miological tracking [23]. The C. urealyticum
isolates were remarkably homogenous and could
be assigned to eight clusters only, despite the
deliberate use of strains from a variety of sources.
Comparison by ribotyping of C. urealyticum
strains from human-related and animal-related
sources revealed predominant ribotypes for each
group of isolates [24]. Some ribotypes were found
only in strains from human-related sources,
whereas others were obtained only from isolates
from animal-related sources. Two isolates with
different antimicrobial susceptibilities exhibited
an identical ribotype, indicating that the geno-
typic profile is more stable than the antibiogram
[24].
THE GENOME SEQUENCE OF
C. UREALYTICUM DSM7109
Very recently, the complete genome sequence of
the type strain C. urealyticum DSM7109 (NCTC
12011; ATCC 43042) [9] has been determined by a
combination of ultrafast pyrosequencing and
Sanger technology [10,25]. The genome of C. ure-
alyticum DSM7109 consists of a circular chromo-
some with a size of 2 369 219 bp and a mean
G + C content of 64.2%, which is close to the
value of 62% that was determined previously by
the thermal DNA denaturation method [9].
Genome annotation revealed 2024 protein-coding
sequences, of which 78% were considered to be
orthologues of genes in the C. jeikeium K411
genome. The close phylogenetic relationship
between C. urealyticum and C. jeikeium is also
reflected by the highly conserved order of
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orthologous genes and the presence of only two
breakpoints in the architecture of the chromo-
some [10].
Metabolic analysis of the genome sequence
provided clear evidence that the lipid-requiring
(‘lipophilic’) phenotype of C. urealyticum is attrib-
utable to the absence of a microbial type I fatty
acid synthase gene and thus represents a fatty
acid auxotrophy [10]. In addition, C. urealyticum is
apparently unable to utilize sugars as carbon and
energy sources because of the absence of charac-
teristic sugar uptake systems and the absence of
genes for anaplerotic functions. Accordingly,
exogenous fatty acids are required not only
to supplement the fatty acid auxotrophy, but also
to serve as sources of carbon and energy for
C. urealyticum. The utilization of exogenous fatty
acids occurs via the b-oxidation pathway and a
large repertoire of auxiliary genes involved in
uptake and degradation of structurally diverse
fatty acid compounds [10]. This comprehensive
gene repertoire reflects the adaptation of C. ure-
alyticum to those habitats on the human skin that
provide an appropriate amount of exogenous
fatty acids for growth.
The urease genes of C. urealyticum DSM7109
are organized in a cluster with the order ure-
ABCEFGD, and seem to play the dominant role in
the pathogenicity of this species [10]. A remark-
able feature of the C. urealyticum DSM7109 gen-
ome sequence is the absence of genes for potential
transcription regulators of the urease gene locus
[26], suggesting that the lack of efficient tran-
scriptional control contributes to the strong urease
activity of C. urealyticum strains [10].
Adherence of C. glutamicum to host tissues may
be mediated by a proteinaceous pilus that is
covalently anchored to the cell wall and encoded
by the structural genes spaDEF and the cognate
sortase genes srtBC in C. urealyticum DSM7109
[10]. Alternatively, only the minor pilin SpaB
might be covalently anchored to the cell wall in
the absence of a pilus shaft to provide tight
contact between the C. urealyticum cell and the
host tissue [10,27,28].
Moreover, the C. urealyticum DSM7109 genome
contains two genes (surA and surB) for cell surface
proteins that display homologies to biofilm-asso-
ciated proteins from Staphylococcus epidermidis
[10]. In particular, the structural similarities and
potential variations in the number of internal
repeat units among different C. urealyticum
strains suggested that these proteins contribute
to an evasion of the immune system and to the
formation of biofilms on medical devices, such as
urinary catheters. The predicted surface proteins
SurA and SurB may thus play important roles in
UTIs in catheterized patients.
ANTIMICROBIAL SUSCEPTIBILITY
The susceptibility pattern of C. urealyticum with
respect to antimicrobial agents varies among
isolates obtained from different sources [24].
C. urealyticum strains from humans and human-
related sources were more frequently resistant to
ampicillin, gentamicin, norfloxacin, erythromycin
and rifampin than were isolates from animals and
animal-related sources. The higher rate of antibi-
otic resistance in strains from humans and
human-related sources may be due to selective
pressure of antibiotics in the human environment
and especially the hospital setting [24,29]. The
majority of C. urealyticum strains obtained from
clinical samples typically display multiple resis-
tance to antibiotics [19,30,31]. C. urealyticum
is normally highly resistant to b-lactams and
aminoglycosides, and variably susceptible to
fluoroquinolones, macrolides, ketolides, rifampin,
and tetracyclines [5,32–44]. C. urealyticum strains
are, however, uniformly susceptible to the
glycopeptides vancomycin and teicoplanin
[5,31,35,37,39,41,43]. The psychiatric drug sertra-
line significantly enhanced the activity of cipro-
floxacin and tetracycline against C. urealyticum
[45].
C. urealyticum isolates were previously found
to be susceptible to ofloxacin, norfloxacin, and
ciprofloxacin [32,33,46], but more recent studies
revealed an increased level of resistance to fluor-
oquinolones [35,36,41,43,47,48]. A recent study
indicated that only 20.3% of the tested C. urealyt-
icum isolates (64 strains) were susceptible to
ciprofloxacin [43]. Newer fluoroquinolones, such
as clinafloxacin, gemifloxacin, levofloxacin, and
ofloxacin, are more effective in vitro than cipro-
floxacin and norfloxacin, but may remain ineffec-
tive against high-level ciprofloxacin-resistant
isolates [40,41,43,48]. Likewise, the ketolide
telithromycin is more active in vitro than the
macrolide erythromycin, but only against eryth-
romycin-susceptible and erythromycin-interme-
diate isolates [39,40,43], whereas the ketolide
cethromycin (ABT-773) is only poorly active
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against C. urealyticum [42]. On the other hand,
newer antibiotics, such as linezolid and quinupri-
stin–dalfopristin, proved to be effective in vitro
against C. urealyticum strains [39,43,44]. These
antibiotics may be useful alternatives to glyco-
peptides in the treatment of C. urealyticum infec-
tions caused by multidrug-resistant strains.
An investigation of external factors contribut-
ing to antimicrobial resistance in C. urealyticum
strains from hospitalized patients revealed that
the use of antibiotics could favour the appear-
ance of multiresistant strains, which were likely
to be acquired directly from the bacterial flora
present in the hospital environment [29]. The
annotated genome sequence of C. urealyticum
DSM7109 provided clear evidence that horizon-
tal gene transfer is the main cause of multiple
resistance to antibiotics [10], as the detected
resistance genes are apparently part of (defec-
tive) mobile genetic elements (Table 1). Highly
similar, or even identical, antibiotic resistance
determinants are well known in other pathogenic
and non-pathogenic corynebacteria [49–54], and
are collectively present on the large multiresis-
tance plasmid pTP10 from C. striatum M82B [50].
Functional analysis of the respective genes
demonstrated that they confer high levels
of resistance to aminoglycosides, macrolides,
lincosamides, telithromycin, chloramphenicol
and tetracyclines in corynebacteria [50,55,56]
and cutaneous propionibacteria [57]. The
repeated detection of the same set of mobile
antibiotic resistance genes in several sequence
analyses (Table 1) indicated that these deter-
minants play a prominent role in conferring
multidrug resistance in corynebacteria [49–54].
EPIDEMIOLOGY
C. urealyticum is the corynebacterium most fre-
quently isolated from clinical specimens, provided
that urine specimens are adequately processed.
The incidence of C. urealyticum varies from
0.016% to 0.32% [7,46,58] among all urine samples
sent for routine culture. The rates of detection may
be increased by a factor of 3–30 if selective media
are used, but even those rates would not not be
clinically relevant [30,46,59–61].
C. urealyticum has been isolated from the skin
of 25–37% of healthy elderly individuals, pre-
dominantly females [62]. This organism has also
been detected in the air of hospital wards
housing colonized and non-colonized patients
but rarely in other dependencies [63]. A possible
hospital outbreak of infection by C. urealyticum,
affecting 15 elderly patients with either an
intravesical catheter or a urinary collector, has
been described [64].
PATHOGENICITY
C. urealyticum is frequently isolated from the
groin in elderly patients receiving broad-spec-
trum antibiotics [62], and this circumstance may
favour colonization of urinary catheters. It has
also been shown that C. urealyticum adheres quite
efficiently to urinary catheters [65], so this organ-
ism may infect the bladder mucosa, especially if
there is an underlying disorder (trauma, tumour,
or inflammation). Strong adherence to uroepithe-
lial cells has been demonstrated [27], and in
bladder biopsies the organism has been seen
completely embedded within the mucosa [5,8].
Table 1. Antibiotic resistance genes detected in the complete genome sequence of Corynebacterium urealyticum DSM7109
Gene Gene product or function
Mobile genetic
element
Resistance spectrum determined in
corynebacteria or propionibacteria Gene(s) previously detected in
erm(X) 23S rRNA adenine N-6-methyltransferase Tn5432-like Azithromycin, clindamycin,
erythromycin, josamycin, lincomycin,
midecamycin, pristinamycin IA,
roxithromycin, spiramycin,
telithromycin, tylosin
C. striatum, C. jeikeium, C. diphtheriae,
cutaneous propionibacteria
aph(3¢)-Ia Aminoglycoside-3¢-phosphotransferase Tn5715-like Kanamycin, lividomycin, neomycin,
paromomycin, ribostamycin
C. striatum
strA–strB Aminoglycoside-3¢¢-phosphotransferase
and aminoglycoside-6-phosphotransferase
Tn5393-like Streptomycina C. striatum
cmx1 ⁄ cmx2 Chloramphenicol exporter of the major
facilitator superfamily
Tn45-like Chloramphenicol C. striatum, C. jeikeium, C. glutamicum
tetA–tetB Tetracycline exporter of the ATP-binding
cassette superfamily
Tn3598-like Tetracycline, oxytetracycline C. striatum
aNot verified experimentally.
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C. urealyticum could also reach the renal pelvis
through a nephrostomy catheter [7] or by an
ascendant route [66].
Once the organism adheres to the urinary tract,
it grows under the stimulation of the urea present
in the urine. The urease leads to hyperammoni-
uria and alkalinization of the urine, which causes
hypersaturation with struvite and calcium phos-
phate with consequent crystallization of struvite
and apatite. These types of urinary stone have
been experimentally reproduced in vitro [67,68]
and in vivo [66,67]. In the same experimental
model, it was shown that bladder instillation of
C. urealyticum can produce both encrusted cystitis
and pyelitis [66].
In addition to stone production and obstructive
complications, urease is also considered to be
responsible for an ammonia-induced cytotoxicity
for the renal epithelium. Therefore options to
neutralize such effect with acetohydroxamic acid
(AHA) have been investigated. In vitro studies
have shown that this drug is able to neutralize the
urease of C. urealyticum, thereby preventing the
formation of struvite crystals [68] and, as some
antibiotics are less active at alkaline pH, com-
pounds such as AHA may also act synergistically
with antibiotics [33].
RISK FACTORS
Most UTIs caused by C. urealyticum occur mainly
in immunocompromised patients with underly-
ing urological disease, patients who have under-
gone urological manipulations, those with a
history of previous UTIs, those hospitalized for
long periods, and those treated with broad-spec-
trum antibiotics [7,8].
Immunosuppression and kidney transplanta-
tion are risk factors for developing pyelonephritis.
Urological diseases, mainly of the bladder, pro-
longed vesical catheterization, and previous UTIs
in patients with chronic debilitating conditions
appear to be the most important risk factors for
the development of encrusted cystitis. Bladders
damaged by trauma, tumour or intravesical
administration of cytotoxic drugs are frequently
the main risk factors for developing encrusted
cystitis [7,8].
Risk factors for encrusted pyelitis are kidney
transplantation, reparative urological surgery
after transplantation, and the use of a pig-tail
ureteral catheter for more than 1 month [69].
UTIs, including pyelonephritis and encrusted
cystitis, may occur at any age (with a mean age of
55–65 years). On the other hand, encrusted pyeli-
tis usually occurs at an earlier age (with a mean
age of 40–45 years). It is of interest that all UTIs
caused by this organism are more frequent in
males than in females. Infections outside the
urinary tract occur at any age, predominantly
also in males, and more than 50% of the cases
occur in patients with urological diseases. The
higher incidence of C. urealyticum infections in
males than in females contrasts with the various
rates of skin colonization by corynebacteria found
in the two sexes [62].
CLINICAL INFECTIONS
Urinary tract infections
Bacteriuria due to C. urealyticum, if properly
investigated, is very common, although true
symptomatic infections occur in fewer than 60%
of the cases [8]. UTIs can be acute or chronic, and
treatments and outcome may differ.
Acute urinary tract infections.
The more common clinical picture is acute cysti-
tis, although in many reported cases no differen-
tiation between cystitis and pyelonephritis was
made [6–8,14,30,46,58,64,69–71]. These patients
suffer from dysuria or urethral discomfort (in
catheterized patients), and frequency and urgency
of urination. Less often, patients have suprapubic
pain or macroscopic haematuria, and only occa-
sionally is gritty material in the urine or low-
grade fever recorded [7,8].
Pyelonephritis was diagnosed in 11 patients,
with simultaneous isolation of the organism from
urine and blood or from urine obtained through a
perirenal catheter, as well as in seven other
patients where the organism was isolated only
from urine [8]. Nearly 80% of these patients were
immunosuppressed. Three bacteraemic patients
were seriously immunosuppressed (leukaemia in
two cases and AIDS in one) and had no previous
renal or urological diseases. Eight patients were
renal transplant recipients and seven others had
previous urological diseases and were older than
60 years [8]. In addition, one case of pyelonephri-
tis was described in a 75-year-old male patient
with bladder carcinoma who underwent cystec-
tomy and nephrostomy [72], and one in a 49-year-
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old male patient without urological disease or
manipulation [73].
Chronic urinary tract infections.
One of the most frequent chronic infections
caused by C. urealyticum is encrusted cystitis.
This is a chronic inflammatory condition with
localized ulcerative inflammation of the bladder,
with deposits of ammonium magnesium phos-
phate on the surface and on the walls of the ulcer
[74]. This disease is associated with infection by a
urea-splitting organism in a bladder that already
harbours an inflammatory or neoplasic lesion.
Such inflammation produces a fibrotic and retrac-
tile bladder with reduced capacity, which may
produce stenosis of the ureteral meatus, leading
to dilatation of the upper urinary tract. This is not
a life-threatening disease, but is a tremendously
painful and disturbing condition. An expert
urologist has stated: ‘si la cystite incruste´e n’est
pas un arreˆt de mort, c’est le supplice a` perpe´tu-
ite´’ [74]. It is thus not surprising that some
patients with this condition become suicidal.
Encrusted cystitis causes long-lasting symptoms
in the lower urinary tract, with frequent relapses
[1,2,5,7,8,30,46,58,69,75–90]. Immunosuppression
is usually less frequent than in patients with
acute infections, but most patients have experi-
enced previous bladder diseases and have under-
gone urological manipulations. The patients
usually suffer from dysuria, suprapubic pain,
haematuria, elimination of gritty material or
struvite stones with the urine, turbid urine, and,
frequently, an ammonia-like odour of the urine.
The urine is usually alkaline, with struvite crys-
tals, pyuria, and haematuria [8]. Plain radio-
graphy can demonstrate bladder calcifications.
Two-dimensional echography of the bladder can
show hyperechogenic foci, and the uroscanner
can show calcified plaques in the bladder. It is
also possible to demonstrate, in some cases,
ureterohydronephrosis [88,90] by echography or
intravenous pyelography. Encrusted cystitis is
usually confirmed by cystoscopy, which, at the
same time, allows the surgical resection of the
encrusted lesions. Bladder biopsies from patients
with encrusted cystitis usually have an ulcerous
necrotic appearance with crystals encrusted
in the chorion and frequent microcolonies of
C. urealyticum [5,7,8].
Another serious chronic infection is encrusted
pyelitis [69,82,85,86,91–98], which has been
mainly described in renal transplant recipients
[69,82,85,86,93–95], but also in native kidneys of
patients with urological diseases [95–97]. It is a
severe event that can destroy the renal graft of
transplanted patients [69,82,85,86,94,98]. The dis-
ease is characterized by the presence of struvite
encrustations on the renal pelvis wall, observed
when the pelvis is open during a urological
intervention [69]. Plain radiography can demon-
strate unusual calcifications in the kidneys and
ureters. Computed tomography can show calcifi-
cations of the pelvis and ureters. Ultrasound
examination of the kidneys may detect hypere-
chogenic material in the pelvis and also hydro-
nephrosis. Intravenous pyelography can show
calcifications, pyelocalicilial dilatation, and corti-
cal hypotrophy. These patients present with UTI
symptoms, pyuria, haematuria, and ammonium
magnesium phosphate crystals in their urine [69].
The kidneys and pyelocalicilial cavities are usu-
ally dilated, with capsular adherences and necro-
tic areas being encrusted with multiple
calcifications [69,82]. Patients with encrusted
pyelitis may develop obstructive uropathy with
deterioration of renal function, pyelonephritis, or
renal abscesses [97]. Another severe complication
is ureteric stricture, which also requires surgical
repair [94,95]. Encrusted pyelitis may also be
complicated by encrusted cystitis [69,82,86]. One
debilitated patient developed encrustations of the
entire upper (pyelitis and ureteritis) and lower
(cystitis) urinary tract and died [84]; another
patient developed shock and died [97].
Other infections
There are 11 well-documented cases of bactera-
emia caused by C. urealyticum [8,69,73,99–101].
The mean age was 52.9 years, and there were
seven males, two females and two patients of
unknown gender; in seven cases, there were
urological disorders [8,69,73,99]. Four patients
had leukaemia [73,100,101] and one had AIDS [8].
Three patients had endocarditis, two on native
valves [75,102] and one on a prosthetic valve
[103]. One native valve endocarditis occurred in a
drug addict and the other in a patient who
developed encrusted cystitis caused by C. urea-
lyticum and died [75]. The third patient had
a valvular prosthesis and an aortic–coronary
bypass, developed endocarditis unrelated to
urinary tract disorders, and died.
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Twelve other kinds of infection have been
described: four wound infections [100], two local-
ized renal infections [104,105], and one each
of peritonitis [14], pericarditis [106], encrusted
urethritis [107], osteomyelitis [108], pneu-
monia [4], and soft tissue infection [109]. Six
of the patients had urological disorders
[14,100,104,105,107] and two were neutropenic,
with breast cancer and acute leukaemia [100,109].
It is of interest that there were urological disor-
ders [8,14,69,73,75,99,100,104,105,107] in 14 of the
26 above-mentioned infections (54%).
MICROBIOLOGICAL DIAGNOSIS
C. urealyticum can be isolated after culture in
several media and mainly on blood agar plates.
Growth in pure culture, or as predominant flora,
especially if seen with polymorphonuclear cells in
Gram-stained samples, is of great value.
Most C. urealyticum isolates are missed in rou-
tine urine cultures because the organism does not
grow after ‘overnight’ incubation. Therefore,
incubation should last longer than 24 h when
patients are symptomatic or have alkaline urine
or struvite crystals in their urine sediment.
The organism grows on blood agar as pin-
point colonies after 48 h of incubation at 35–
37C. Colonies are whitish, opaque, smooth,
convex, circular, entire, and non-haemolytic
[3,5,9,19]. At the time of writing, C. urealyticum
is the only known Corynebacterium species that
is lipophilic, asaccharolytic, and strongly urease-
positive [19]. The final identification can be
easily performed by phenotypic studies
[5,19,36,37], using home-made media or com-
mercial systems [110].
In a case of encrusted cystitis with routine urine
culture being negative, DNA of C. urealyticum
was detected by PCR [83]. A culture-independent,
16S rRNA gene-based approach has been used to
identify this organism in clinical specimens.
Amplicons of the 16S rRNA gene encompassing
the V6–V8 regions have been analyzed with
denaturing HPLC, and the identities of distinct
peak profiles were confirmed by sequencing
individually collected peak products [111]. The
RNA polymerase beta-subunit-encoding gene
(rpoB) can also be used for identification of
Corynebacterium species [17]. Finally, another
molecular technique useful for difficult-to-iden-
tify organisms, including coryneforms, is rRNA
gene sequencing, because of the universal distri-
bution of, and the presence of, species-specific
variable regions in the genes [112,113].
TREATMENT AND OUTCOME
In a large published series, 96% of the patients
receiving an adequate antibiotic were cured or
improved, whereas only 35% (mostly with acute
cystitis) improved with an antibiotic considered
not to be active against C. urealyticum in vitro [8].
Glycopeptides [6–8,69,71,73], mainly vancomycin,
tetracyclines [6,7,58,72], and fluoroquinolones
[7,8,58], have been used with great success in
many patients with UTIs. In some acute UTIs,
AHA has been concurrently administered [8,71].
Most cases of encrusted cystitis have required
surgical resection of the bladder encrustations, as
well as prolonged (more than 1 month) antimi-
crobial treatment. Antibiotics successfully used in
this condition have been glycopeptides [7,8,69,
76–79,83,85,89], tetracyclines [5,7,8,58,83], and
fluoroquinolones [7,8,58,77,80,90]. Teicoplanin
has been successfully used in two patients with
encrusted cystitis caused by C. urealyticum, even
without cystoscopic resection of the stones, which
were spontaneously eliminated [79]. AHA has
been concurrently used in several patients with
encrusted cystitis [8,77,78]. Oral acidification of
the urine has also been recommended as an
adjuvant therapy [5,90].
The outcome in patients with encrusted pyelitis
receiving adequate treatment, especially with
glycopeptides [69,85,93–96], has been favourable.
However, a non-transplanted 70-year-old patient
treated for bladder carcinoma developed
encrusted pyelitis and pyelonephritis and, while
receiving vancomycin combined with fusidic
acid, ureteral catheterization and nephrostomy,
suffered septic shock and died [97]. AHA has also
been used in this condition [93,95,96]. Ureteros-
tomy and graft removal have also been necessary
for the management of similar conditions
[69,82,85,86,94,98]. Five renal transplant recipients
developed encrusted pyelitis (four cases) and
encrusted cystitis (one case), and all were suc-
cessfully treated with vancomycin, but all patients
required a derivative procedure or a surgical
resection of the encrustations to improve [69]. Six
patients were treated with vancomycin, percuta-
neous acidification of the renal collecting system
for chemolysis [93,95,96] and, in some cases,
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administration of AHA. With this conservative
treatment, it has been possible to dissolve encrus-
tations within 2 months [95], with preservation of
renal function and without renal loss.
In one case of endocarditis due to Corynebacte-
rium group D2, a young drug addict was success-
fully treated with replacement of the aortic and
mitral valves in conjunction with a 4-week course
of vancomycin [102]. In other cases of endocardi-
tis, one patient did not receive adequate treatment
and died [75], and one, although receiving appar-
ently adequate treatment, died shortly after the
surgical procedure [103].
Nine bacteraemic patients were treated with an
antibiotic active in vitro against C. urealyticum
[8,69,70,101], mainly vancomycin, and one by a
partial nephrectomy [99]. One neutropenic patient
with acute myeloblastic leukaemia and catheter-
related bacteraemia was cured after a course of
vancomycin in conjunction with catheter removal,
but this also coincided with an increase in
neutrophil counts [101]. Another neutropenic
patient developed septicaemia caused by C. ure-
alyticum and Candida albicans and died [100]. All
other patients recovered.
Among 12 patients with other infections, ten
were successfully treated with vancomycin
[14,100,105–109], with or without surgery, and
one neutropenic patient recovered, with a coin-
ciding increase in polymorphonuclear cells [109].
One patient with pneumonia caused by a peni-
cillin-sensitive strain was successfully treated
with this antibiotic [4], and in the remaining case
[104] a ureterocalycostomy with lower-pole resec-
tion was necessary for cure. All patients recov-
ered uneventfully, and no mortality directly
related to the infection was observed.
Development of resistance during treatment
has been observed with beta-lactam antibiotics
[71], fluoroquinolones [8,71,81], macrolides [8,81],
rifampin, tetracycline, and gentamicin [8].
CONCLUSIONS
The complete genome sequence of C. urealyticum
has been determined by a combination of pyrose-
quencing and Sanger technology. The chromo-
some of the type strain has a size of 2.37 Mbp,
containing 2024 predicted coding sequences, and
revealed a detailed picture of the lifestyle of this
opportunistic pathogen, including potential
mechanisms of multidrug resistance. C. urealyti-
cum is not a rare cause of infection, especially in
patients with urological diseases and in immuno-
compromised patients. For diagnosing human
infections caused by C. urealyticum, strong collab-
oration between microbiologists, infectious dis-
eases specialists and urologists is necessary.
Clinical specimens must be correctly taken, trans-
ported, and processed. Urine specimens should
be incubated for longer than 24 h (48–72 h) when
patients present symptoms of or have alkaline
urine or struvite crystals in their urine sediment.
The resistance of this organism to multiple anti-
biotics dictates that empirical therapy with a
glycopeptide antibiotic should be used until the
results of susceptibility testing are available. It
appears that successful therapy for chronic infec-
tion due to C. urealyticum often requires removal
of an infected foreign body or surgical interven-
tion. The prognosis for patients with infections
caused by C. urealyticum appears to be reasonably
good if the microbiological diagnosis is made and
medical and surgical intervention is timely.
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